{"entity":{"id":"nct07322341","kind":"trial","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of atezolizumab in lung cancer, run by University of Washington, now recruiting.","summary":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT07322341 by University of Washington, with a registry enrolment figure of 32 participants, started 2026-10-01 and due to reach its primary completion in 2030-11-01. Interventions recorded: Atezolizumab; CXCR1/2 Inhibitor SX-682; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Biopsy Procedure. Conditions listed: Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Objective response rate. Lung eligibility wording from the registry: \"* Pathologically or cytologically confirmed non-small cell lung cancer with no known oncogenic EGFR mutation, ALK fusion, ROS1 fusion or RET fusions\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07322341","url":"https://clinicaltrials.gov/study/NCT07322341"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07322341","phase":"2","setting":"A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy","sponsor":"University of Washington","enrolled":32,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07322341/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}